Your browser doesn't support javascript.
Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement.
Hamad, Nada; Ananda-Rajah, Michelle; Gilroy, Nicole; MacIntyre, Raina; Gottlieb, David; Ritchie, David; Harrison, Simon; Kennedy, Glen; Watson, Anne M; Greenwood, Matthew; Doocey, Richard; Perera, Travis; Spencer, Andrew; Wong, Eric; O'Brien, Tracey; Shaw, Peter; Conyers, Rachel; Milliken, Samuel; Bardy, Peter; Larsen, Stephen; Ho, Phoebe J; Lai, Hock; Bajel, Ashish; Butler, Jason; Tiley, Campbell; D'Rozario, James; Johnston, Anna; Cochrane, Tara; Mills, Tony; Irving, Ian; Pullon, Humprey; Purtill, Duncan.
  • Hamad N; St Vincent's Hospital Sydney and University of New South Wales, Sydney, New South Wales, Australia.
  • Ananda-Rajah M; Monash Institute of Medical Engineering and Alfred Health, Melbourne, Victoria, Australia.
  • Gilroy N; Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, New South Wales, Australia.
  • MacIntyre R; Kirby Institute and University of New South Wales, Sydney, New South Wales, Australia.
  • Gottlieb D; University of Sydney and Westmead Hospital, Sydney, New South Wales, Australia.
  • Ritchie D; Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Harrison S; Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Kennedy G; Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
  • Watson AM; Liverpool Hospital, Sydney, New South Wales, Australia.
  • Greenwood M; Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Doocey R; Auckland City Hospital, Auckland, New Zealand.
  • Perera T; Wellington Blood and Cancer Centre, Wellington, New Zealand.
  • Spencer A; The Alfred Hospital and Monash University, Melbourne, Victoria, Australia.
  • Wong E; Austin Hospital, Melbourne, Victoria, Australia.
  • O'Brien T; Sydney Children's Hospital, Sydney, New South Wales, Australia.
  • Shaw P; University of Sydney and Westmead Hospital, Sydney, New South Wales, Australia.
  • Conyers R; The Royal Children's Hospital, Melbourne, Victoria, Australia.
  • Milliken S; St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
  • Bardy P; Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Larsen S; Royal Prince Alfred Hospital and the University of Sydney, Sydney, New South Wales, Australia.
  • Ho PJ; Royal Prince Alfred Hospital and the University of Sydney, Sydney, New South Wales, Australia.
  • Lai H; Townsville Hospital, Townsville, Queensland, Australia.
  • Bajel A; Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Butler J; Liverpool Hospital, Sydney, New South Wales, Australia.
  • Tiley C; Gosford Hospital and University of Newcastle, Newcastle, New South Wales, Australia.
  • D'Rozario J; Canberra Hospital, Canberra, Australian Capital Territory, Australia.
  • Johnston A; Royal Hobart Hospital, Hobart, Tasmania, Australia.
  • Cochrane T; Gold Coast University Hospital, Gold Coast, Queensland, Australia.
  • Mills T; Princess Alexandria Hospital, Brisbane, Queensland, Australia.
  • Irving I; ICON Cancer Centre, Brisbane, Queensland, Australia.
  • Pullon H; Waikato Hospital, Hamilton, New Zealand.
  • Purtill D; Fiona Stanley Hospital, Perth, Western Australia, Australia.
Intern Med J ; 51(8): 1321-1323, 2021 08.
Article in English | MEDLINE | ID: covidwho-1367321
ABSTRACT
Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as well as representatives from autologous transplant only centres in Australia and New Zealand collaborated with infectious diseases specialists with expertise in TCT on this consensus position statement regarding COVID-19 vaccination in TCT patients in Australia and New Zealand. It is our recommendation that TCT patients, should have expedited access to high-efficacy COVID-19 vaccines given that these patients are at high risk of morbidity and mortality from COVID-19 infection. We also recommend prioritising vaccination of TCT healthcare workers and household members of TCT patients. Vaccination should not replace other public health measures in TCT patients given the effectiveness of COVID-19 vaccination in TCT patients is unknown. Furthermore, given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Transplant Recipients / COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Child / Humans Country/Region as subject: Oceania Language: English Journal: Intern Med J Journal subject: Internal Medicine Year: 2021 Document Type: Article Affiliation country: Imj.15263

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Transplant Recipients / COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Child / Humans Country/Region as subject: Oceania Language: English Journal: Intern Med J Journal subject: Internal Medicine Year: 2021 Document Type: Article Affiliation country: Imj.15263